For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>Salinomycin is an antibacterial and coccidiostat ionophore therapeutic drug.<br>IC50 Value:<br>Target: Antibacterial; Anticancer<br>Salinomycin, a polyether ionophore antibiotic isolated from Streptomyces albus, has been shown to kill CSCs in different types of human cancers, most likely by interfering with ABC drug transporters, the Wnt/β-catenin signaling pathway, and other CSC pathways[1].<br>in vitro: Salinomycin acts as a potassium ionophore and thereby interferes with transmembrane potassium potential, leading to mitochondrial and cellular potassium efflux. low concentrations of Salinomycin of 1 μM and 2 μM resulted in haggard and less confluent grown cells, increasing concentrations of Salinomycin of 5 μM and 10 μM resulted in a globular and defragmented cellular phenotype[2]. Treatment of 10.2 uM Sal for 48 h caused G0/G1 cell cycle arrest in HepG2 cells, whereas 15.3 uM Sal and 13.8 uM Sal for 48 h induced G2/M phase arrest in SMMC-7721 and BEL-7402 cells, respectively[3].<br>in vivo: After administration of 4 mg/kg Sal, 8 mg/kg Sal and 10 ul/g saline water for 6 weeks, the mice were sacrificed. The size of the liver tumors in the Sal treatment groups diminished compared with the control group. The mean diameter of the tumors decreased from 12.17 mm to 3.67 mm and the mean volume of the tumors decreased from 819 mm3 to 25.25 mm3 . Next, the tumors were harvested, followed by HE staining, immunohistochemistry, and TUNEL assays, to assess the anti-tumor activity of Sal in vivo[3].<br><br></p>
| Catalog Number | I003938 |
| CAS Number | 53003-10-4 |
| Synonyms | Procoxacin |
| Molecular Formula | C42H70O11 |
| Purity | ≥95% |
| Target | Wnt/β-catenin |
| Solubility | DMSO 23 mg/ml |
| Storage | 3 years -20C powder |
| InChI | InChI=1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23- |
| InChIKey | KQXDHUJYNAXLNZ-XQSDOZFQSA-N |
| SMILES | CC[C@@H](C(O)=O)[C@H]1CC[C@@H]([C@H]([C@H]([C@@H]([C@@H](C([C@@H]([C@H]2O[C@]3([C@@H](C[C@@H]2C)C)O[C@]4([C@@H](C=C3)O)CC[C@](O4)([C@H]5CC[C@](CC)([C@@H](O5)C)O)C)CC)=O)C)O)C)O1)C |
| Reference | </br>1:Inhibition of Autophagy Promotes Salinomycin-Induced Apoptosis via Reactive Oxygen Species-Mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in Human Prostate Cancer Cells. Kim KY, Park KI, Kim SH, Yu SN, Park SG, Kim YW, Seo YK, Ma JY, Ahn SC.Int J Mol Sci. 2017 May 18;18(5). pii: E1088. doi: 10.3390/ijms18051088. PMID: 28524116 </br>2:Salinomycin induces endoplasmic reticulum stress‑mediated autophagy and apoptosis through generation of reactive oxygen species in human glioma U87MG cells. Yu SN, Kim SH, Kim KY, Ji JH, Seo YK, Yu HS, Ahn SC.Oncol Rep. 2017 May 2. doi: 10.3892/or.2017.5615. [Epub ahead of print] PMID: 28498472 </br>3:Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells. Tung CL, Chen JC, Wu CH, Peng YS, Chen WC, Zheng HY, Jian YJ, Wei CL, Cheng YT, Lin YW.Exp Cell Res. 2017 Apr 25. pii: S0014-4827(17)30253-7. doi: 10.1016/j.yexcr.2017.04.026. [Epub ahead of print] PMID: 28454878 </br>4:Salinomycin overcomes radioresistance in nasopharyngeal carcinoma cells by inhibiting Nrf2 level and promoting ROS generation. Zhang G, Wang W, Yao C, Ren J, Zhang S, Han M.Biomed Pharmacother. 2017 Apr 25;91:147-154. doi: 10.1016/j.biopha.2017.04.095. [Epub ahead of print] PMID: 28453992 </br>5:Therapeutic PEG-ceramide nanomicelles synergize with salinomycin to target both liver cancer cells and cancer stem cells. Wang M, Xie F, Wen X, Chen H, Zhang H, Liu J, Zhang H, Zou H, Yu Y, Chen Y, Sun Z, Wang X, Zhang G, Yin C, Sun D, Gao J, Jiang B, Zhong Y, Lu Y.Nanomedicine (Lond). 2017 May;12(9):1025-1042. doi: 10.2217/nnm-2016-0408. Epub 2017 Apr 25. PMID: 28440698 </br>6:Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells. Dunlop EA, Johnson CE, Wiltshire M, Errington RJ, Tee AR.Oncotarget. 2017 Mar 15. doi: 10.18632/oncotarget.16232. [Epub ahead of print] PMID: 28415776 Free Article</br>7:Mechanism of salinomycin overproduction in Streptomyces albus as revealed by comparative functional genomics. Zhang X, Lu C, Bai L.Appl Microbiol Biotechnol. 2017 Apr 11. doi: 10.1007/s00253-017-8278-5. [Epub ahead of print] PMID: 28401259 </br>8:Salinomycin attenuates liver cancer stem cell motility by enhancing cell stiffness and increasing F-actin formation via the FAK-ERK1/2 signalling pathway. Sun J, Luo Q, Liu L, Yang X, Zhu S, Song G.Toxicology. 2017 Jun 1;384:1-10. doi: 10.1016/j.tox.2017.04.006. Epub 2017 Apr 8. PMID: 28395993 </br>9:Salinomycin Induces Reactive Oxygen Species and Apoptosis in Aggressive Breast Cancer Cells as Mediated with Regulation of Autophagy. Kim KY, Park KI, Kim SH, Yu SN, Lee D, Kim YW, Noh KT, Ma JY, Seo YK, Ahn SC.Anticancer Res. 2017 Apr;37(4):1747-1758. PMID: 28373437 </br>10:Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis. Bi YL, Mi PY, Zhao SJ, Pan HM, Li HJ, Liu F, Shao LR, Zhang HF, Zhang P, Jiang SL.Int J Mol Med. 2017 May;39(5):1255-1261. doi: 10.3892/ijmm.2017.2940. Epub 2017 Mar 29. PMID: 28358414 Free PMC Article |
